VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, discusses the impact of pre-transplant molecular measurable residual disease (MMRD) and European Leukemianet (ELN) genetic classification in clinical outcomes for acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (alloHCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter